LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced an expansion of its collaboration with The University of Texas MD ...

Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for ...

At The University of Texas MD Anderson Cancer Center, our mission has always been clear: to end cancer. Achieving this goal requires more than just groundbreaking research and exceptional patient care ...

Ochsner Health is expanding its partnership with The University of Texas MD Anderson Cancer Center to Slidell Memorial Hospital, bringing one of the nation’s most advanced cancer treatment programs to ...

Ochsner MD Anderson Cancer Center at The Gayle and Tom Benson Cancer Center in New Orleans announces a milestone in advanced ...

Naval Daver, MD, who leads a number of acute myeloid leukemia (AML) research trials at MD Anderson Cancer Center in Houston, looks forward to a future where the treatment for AML is truly personalized ...

In an interview with Targeted Oncology, Paolo Strati, MD, associate professor in the Department of Lymphoma/Myeloma in the ...

First radiotherapeutic agent developed by Radiopharm Ventures, the joint venture between Radiopharm Theranostics and MD Anderson Cancer Center ...

Major themes include advances in actionable biomarkers in pancreatic cancer, proton therapy, artificial intelligence and theranostics MD Anderson researchers will present more than 65 abstracts, ...

NEW YORK, Nov. 18, 2025 /PRNewswire/ -- The DeGregorio Family Foundation with support from the Torrey Coast Foundation has awarded a $500,000 Michael F. Price Memorial Grant to Katy Rezvani, MD, PhD, ...